Swiss Biotech Day: Basel based Nouscom presented data at AACR last week on its cancer vaccine that is meant to lower the risk of Lynch Syndrome carriers from having future cancers
- May 5, 2025
- 1 min read
CEO Marina Udier describes the vaccine's design, what was presented at AACR, and discussions the company has had with U.S. FDA about running a registrational study. Plus, previewing upcoming data later this year in metastatic colorectal cancer.
.png){kind=logo}